MedTrace Logo

Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions(DDI) Among Osteoarthritis Patients

NCT01177267 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2012-05-01

No results posted yet for this study

Summary

Using a retrospective database analysis, OA patients taking at least one CYP450-metabolized opioid (codeine, fentanyl, hydrocodone, methadone, oxycodone, or tramadol) and at least one other prescription drug metabolized via the CYP450 system were evaluated for an incident drug-drug exposure (DDE), which places them at risk for experiencing a pharmacokinetic drug-drug interaction (DDI).

Conditions

Sponsors & Collaborators

  • NEMA Research, Inc.

    lead INDUSTRY

Principal Investigators

  • Joseph Pergolizzi, MD · NEMA Research

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2010-12-31
Completion
2011-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01177267 on ClinicalTrials.gov